Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Myasthenia Gravis 1Multiple Myeloma 1Hematologic Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Immunoglobulins, Intravenous × Clear all
NCT04634435 2025-01-20

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Biohaven Pharmaceuticals, Inc.

Phase 1 Completed
7 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00515450 2010-07-30

Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

Benesis Corporation

Phase 3 Completed
46 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡